Breaking News

Piramal Pharma Ltd. Invests Minority Stake in CDMO Yapan Bio

The investment of INR 101.77 cror in biologics reflects the company’s global commitment to this fast-growing segment of the pharma industry.

Author Image

By: Charlie Sternberg

Associate Editor

Piramal Pharma Limited (PPL) has invested INR 101.77 crore in Yapan Bio Pvt Ltd of Hyderabad, India, augmenting the capabilities of its Contract Development and Manufacturing Organization (CDMO) business, Piramal Pharma Solutions (PPS).   PPL holds 27.78% equity stake in the company as a result of this investment. This acquisition marks a significant addition to PPS’ global capabilities in the development and manufacturing of large molecules for human clinical trials. About Yapan Bio Yapan Bio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters